Pacritinib Effectiveness in Real-world Settings

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, retrospective chart review examines how pacritinib is used in routine care for myelofibrosis patients and what outcomes occur, including blood counts, clinical events, and survival. Data are collected solely from existing medical records with no new testing or procedures. Eligible patients are adults with MF who started pacritinib with a platelets count of at least 50, and who had at least 1 month of therapy and 6 months of observation unless they died within 6 months. The study relies on chart abstraction to capture treatment patterns and outcomes in real-world practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients must be ≥18 years of age at the index date
* Patients diagnosed with MF with platelet counts ≥50 x 109/L at the time of treatment initiation with pacritinib. If multiple values are available within 30 days prior to initiating treatment with pacritinib will use the value closest to index date
* Patients will be required to have ≥1 month of treatment with pacritinib and ≥6 months of observation from the start of pacritinib unless the patient died within 6 months of starting pacritinib
* If peripheral blasts were evaluated prior to index, they must be \<10%. If not evaluated, patients will be included unless a healthcare provider has indicated in the medical record that there is a concern that the patient has transitioned to accelerated/blast phase disease at or prior to index
* According to local regulations, waivers of consent will be sought for study patients from the appropriate regulatory authorities and/or the independent ethics committee (IEC)/institutional review board (IRB). For patients not covered by waivers of consent, signed and dated informed consent provided by the patient, or the patient's legally authorized representative(s) for patients under the legal age (with patient assent, as applicable), should be obtained before any study-related activities are undertaken.

Exclusion Criteria:

* Diagnosis of acute myeloid leukemia prior to index
* Physician-concern that the patient has transitioned to accelerated/blast phase disease if peripheral blasts were not evaluated
* Treated with 2 or more JAK inhibitors prior to initiating treatment with pacritinib
* Treated with pacritinib in a clinical trial setting

Where it's running

• Yale School of Medicine
  New Haven, Connecticut, United States Recruiting
• Tampa General Hospital
  Tampa, Florida, United States Recruiting
• The Ohio State University
  Columbus, Ohio, United States Recruiting
• Medical University of South Carolina
  Charleston, South Carolina, United States Recruiting
• OneOncology Research Network
  Nashville, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Raman Garcha, MD — Swedish Orphan Biovitrum
• Study coordinator: IQVIA Study Team
• Email: PACER-study@mail.iqvia.com
• Phone: 617-621-1600

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• MPNdpoint: Long-term Look at Philadelphia-negative Myeloproliferative Neoplasms

  This study tests how outcomes differ for patients 16 and older with polycythemia vera, essential thrombocythemia, or myelofibrosis by collecting and analyzing clinical and treatment data.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07863466

• PRT12396 for people with high-risk polycythemia vera or myelofibrosis

  The team will try the oral drug PRT12396 in people with high-risk polycythemia vera or myelofibrosis to find safe doses and look for early signs of benefit.

  Recruiting at 22 sites Phase 1 Prelude Therapeutics Incorporated · Los Angeles, California and 21 other locations · NCT07469891

• Pacritinib and Selinexor in JAK-inhibitor naive myelofibrosis with anemia and low platelets

  This trial tests whether combining pacritinib and selinexor helps patients with myelofibrosis who have anemia and low platelets and have not yet tried a JAK inhibitor.

  Recruiting Phase 2 Icahn School of Medicine at Mount Sinai · Westwood, Kansas and 2 other locations · NCT07447817

• CCR2-based blood test and PET imaging to detect bone marrow fibrosis in myeloproliferative neoplasms

  This project tests whether a blood test measuring CCR2-positive cells and a CCR2-targeted PET scan can find and track bone marrow fibrosis in adults with myeloproliferative neoplasms.

  Recruiting Azienda Ospedaliero-Universitaria di Parma · Parma, Italy · NCT07419178

• Pacritinib for bone marrow fibrosis in myelofibrosis with low platelets

  This trial will test if pacritinib can reduce bone marrow fibrosis and help restore blood counts in adults with myelofibrosis who have low platelets (50–120 × 10^9/L).

  Recruiting at 12 sites Phase 2 Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas · Barcelona, Barcelona and 12 other locations · NCT07394153

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.